Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX: MHC.U; MHC.UN) today released its third quarter 2025 results. The financial results of the REIT are prepared in ...
According to experts from Towards Packaging, the global multilingual packaging market is projected to experience steady growth throughout the forecast period, expanding significantly by 2034.Ottawa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback